{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T12:56:44Z","timestamp":1777553804757,"version":"3.51.4"},"reference-count":20,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100007834","name":"Ningbo Natural Science Foundation","doi-asserted-by":"crossref","award":["2022J039"],"award-info":[{"award-number":["2022J039"]}],"id":[{"id":"10.13039\/100007834","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Dose-Response"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study compared the efficacy of different doses of filgotinib (100 mg vs 200 mg) in the treatment of rheumatoid arthritis (RA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a systematic review of 4 electronic databases up to January 2025. Primary outcome measures included ACR20, ACR50, ACR70.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Five RCTs were included in this analysis, in which 2191 patients with RA were evaluated, 100 mg filgotinib was noninferior to 200 mg filgotinib in the efficacy of ACR20 (P = 0.33, RR = 0.96). However, 100 mg filgotinib was inferior to 200 mg filgotinib for RA when using ACR50 (P = 0.04, RR = 0.92) and ACR70 (P = 0.02, RR = 0.86) as outcome measures. At 24 weeks, 100 mg filgotinib was inferior to 200 mg filgotinib at ACR50 (P = 0.07, RR = 0.84), and there was no significant difference between 100 mg and 200 mg filgotinib at ACR70 (P = 0.54, RR =0.88). The 52-week results showed 100 mg filgotinib was inferior to 200 mg filgotinib at ACR70 (P = 0.01, RR = 0.86).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Reduced dose filgotinib (100 mg) may be used as a potential treatment option for RA when treatment is required.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/15593258261441407","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T05:25:29Z","timestamp":1775193929000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of the Efficacy of Different Doses of Filgotinib in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis Based on the RCTs"],"prefix":"10.1177","volume":"24","author":[{"given":"Xia","family":"Ye","sequence":"first","affiliation":[{"name":"Ningbo Hospital of Integrated Traditional Chinese and Western Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sidong","family":"Zhu","sequence":"additional","affiliation":[{"name":"Zhejiang Chinese Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongying","family":"Wang","sequence":"additional","affiliation":[{"name":"Zhejiang Chinese Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lifeng","family":"Hu","sequence":"additional","affiliation":[{"name":"Ningbo Yinzhou No. 3 Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yudie","family":"Li","sequence":"additional","affiliation":[{"name":"Ningbo Yinzhou No. 3 Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingping","family":"Wu","sequence":"additional","affiliation":[{"name":"Zhejiang Chinese Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingqi","family":"Chen","sequence":"additional","affiliation":[{"name":"Zhejiang Chinese Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6428-8248","authenticated-orcid":false,"given":"Bangsheng","family":"Chen","sequence":"additional","affiliation":[{"name":"Ningbo Hospital of Integrated Traditional Chinese and Western Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2026,4,2]]},"reference":[{"key":"e_1_3_7_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2018.1"},{"key":"e_1_3_7_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-022-01129-y"},{"key":"e_1_3_7_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-225759"},{"key":"e_1_3_7_5_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0338188"},{"key":"e_1_3_7_6_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2700"},{"key":"e_1_3_7_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.22552"},{"key":"e_1_3_7_8_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224742"},{"key":"e_1_3_7_9_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557"},{"key":"e_1_3_7_10_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210104"},{"key":"e_1_3_7_11_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219213"},{"key":"e_1_3_7_12_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.9055"},{"key":"e_1_3_7_13_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-018-1541-z"},{"key":"e_1_3_7_14_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219214"},{"key":"e_1_3_7_15_2","doi-asserted-by":"publisher","DOI":"10.1080\/1744666x.2023.2149495"},{"key":"e_1_3_7_16_2","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-020-00535-z"},{"key":"e_1_3_7_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-94894-2"},{"key":"e_1_3_7_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-022-00503-3"},{"key":"e_1_3_7_19_2","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/4g8g9q"},{"key":"e_1_3_7_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-023-00583-9"},{"key":"e_1_3_7_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.40186"}],"container-title":["Dose-Response"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15593258261441407","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/15593258261441407","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15593258261441407","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T18:03:08Z","timestamp":1777399388000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/15593258261441407"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1177\/15593258261441407"],"URL":"https:\/\/doi.org\/10.1177\/15593258261441407","relation":{},"ISSN":["1559-3258","1559-3258"],"issn-type":[{"value":"1559-3258","type":"print"},{"value":"1559-3258","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"article-number":"15593258261441407"}}